RxDoctor Payments Data

Charles Newcomer

Optometrist · Jasper, GANPI 1659943363

Payments from drug & device makers

$1,066in general payments, 2019–2025

Across 42 payments — averaging $25.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$270
  • AbbVie$189
  • Alcon$176
  • Glaukos Corporation$109
  • Amgen$84
  • Novartis$61
  • plus $178 from 6 others

What the payments were for

  • Food & beverage$1,066100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,066 in reported general payments places this provider in the 55th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$62,007
Medicare patients
399
Services billed
716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine32$27,348
XiidraLifitegrast15$10,140
Cyclosporine28$9,453
Prednisolone Acetate58$2,391
Latanoprost122$1,469
ErythromycinErythromycin Base78$796
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat33$792
ValacyclovirValacyclovir Hcl14$728
Brimonidine Tartrate24$265
MoxifloxacinMoxifloxacin Hcl12$234
Timolol Maleate26$203
Doxycycline Hyclate11$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$189$27,34832 claims
Bausch & Lomb Americas Inc.Xiidra$53$10,14015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Jasper

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →